Mellemkjaer Lene, Blot William J, Sørensen Henrik Toft, Thomassen Lars, McLaughlin Joseph K, Nielsen Gunnar Lauge, Olsen Jørgen H
Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark.
Br J Clin Pharmacol. 2002 Feb;53(2):173-81. doi: 10.1046/j.0306-5251.2001.01220.x.
It is well-known that use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of upper gastrointestinal bleeding (UGIB), but characteristics of the association and quantification of excess risk at the population level require clarification.
All users of nonaspirin prescription NSAIDs in North Jutland County, Denmark during 1991-95 were identified in the regional Pharmaco-Epidemiologic Database. Using the Hospital Discharge Register, all hospitalizations for UGIBs were identified among the 156,138 users of NSAIDs and compared with the number of expected based on the North Jutland population who did not receive NSAID prescriptions.
During periods of NSAID use without use of other drugs associated with UGIB, we observed 365 UGIBs, a number 3.6 times higher than expected (95% CI = 3.3, 4.0). The excess risk varied by sex, type of NSAID and form and route of administration of the NSAID, but not by age at first NSAID prescription or number of prior prescriptions. Risk declined sharply following cessation of use. For ibuprofen and naproxen, there was a clear trend in rising risk by increasing dose, although the lowest doses were also associated with an excess of UGIB. Concurrent use of corticosteroids, anticoagulants and aspirin further increased the risk of UGIB.
All types and formulations of NSAIDs appear to increase the risk of UGIBs, but the effect appear not to be cumulative and diminish rapidly with discontinue of use. Up to 15% of the UGIBs in the entire population of the North Jutland County may be explained by use of this drug.
众所周知,使用非甾体抗炎药(NSAIDs)会增加上消化道出血(UGIB)的风险,但这种关联的特征以及人群水平上额外风险的量化尚需阐明。
在丹麦北日德兰郡地区的药物流行病学数据库中识别出1991 - 1995年期间所有使用非阿司匹林处方NSAIDs的患者。利用医院出院登记册,在156,138名NSAIDs使用者中识别出所有因UGIB住院的病例,并与未接受NSAIDs处方的北日德兰郡人群预期病例数进行比较。
在未使用与UGIB相关的其他药物的NSAIDs使用期间,我们观察到365例UGIB病例,这一数字比预期高3.6倍(95%可信区间 = 3.3, 4.0)。额外风险因性别、NSAIDs类型以及NSAIDs的剂型和给药途径而异,但不因首次使用NSAIDs时的年龄或既往处方数量而有所不同。停药后风险急剧下降。对于布洛芬和萘普生,随着剂量增加风险有明显上升趋势,尽管最低剂量也与UGIB过量相关。同时使用皮质类固醇、抗凝剂和阿司匹林会进一步增加UGIB的风险。
所有类型和剂型的NSAIDs似乎都会增加UGIB的风险,但这种影响似乎不是累积性的,且在停药后迅速减弱。北日德兰郡整个人口中高达15%的UGIB病例可能可归因于该药物的使用。